

INTERMEDIATES



EVEREST
ORGANICS LIMITED 



Delivering innovative, customer-focused products

Choose Everest Organics Limited

About us:

Founded in 1993, the company specialized in manufacturing API's and Intermediates with its manufacturing facility in Sadasivpet, Hyderabad (50 km from Rajiv Gandhi International Airport).

In 1995, the company became a public listed company and was listed on the BSE, We are a two times USFDA approved Company.

Everest Organics Limited is headed by seasoned professionals who have strong expertise in the field of medical science, marketing and business administration.

Our Vision

We envision to become a global generic player with a strong regulatory focus. We strive with utmost effort and strong determination to meet the challenge of combining our individual competencies to deliver new innovative and life saving API's, at the same time ensuring customer centric service as well.

Our Mission

To develop a well-thought-out plan for producing both mainstream, specialized APIs & intermediates, with a firm commitment to produce high-quality product while being completely accessible to all our stakeholders.



Sl. No	Product	DMF	Tech Pack	CAS No.
Febuxostat Intermediate				
1	Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5- Thiazolecarboxylate	-	✓	161797-99-5
2	Ethyl 2-(3-Formyl -4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate	-	✓	161798-01-2
3	Ethyl 2-(3-Formyl -4-Isobutoxyphenyl)-4-Methylthiazole-5- Carboxylate	-	✓	161798-03-4
4	Ethyl 2-(3-Cyano -4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate	-	✓	160844-75-7
Ilaprazole Intermediate				
5	2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride	-	✓	124473-12-7
6	2-(4-Methoxy-3-Methylpyridin-2-yl methyl)-5-(1H-Pyrrol-1-yl) -11H-Benzo[d]imidazole	-	✓	172152-35-1
7	5-(1H-Pyroll-1-yl)-2-Mercaptobenzimidazole	-	✓	172152-53-3
Oseltamivir Phosphate Intermediate				
8	Ethyl (1S, 5R,6R)-5-(Pentan-3-yloxy)-7-oxabicyclo [4.1.0]hept-3-ene-3-carboxyl	-	✓	204254-96-6
9	Ethyl (3r,4r,5s)-4-acetamido-5-azido -3-(1-ethylpropoxy) cyclohex-1-ene-1-Carboxylate	-	✓	204255-06-1
10	(3R,4R,5S)-Ethyl 4-(n-(tert-butyl)acetamido)-5-(diallylamino) -3-(pentan -3-yloxy)Cyclohex-1-enecarboxylate Hydrochloride	-	✓	651324-08-2
Rivaroxaban Intermediate				
11	4-(4-Aminophenyl) Morpholin-3-one	-	✓	438056-69-0
12	2-(S)-Oxiran-2ylMethyl)Isoindoline-1,3-Dione	-	✓	161596-47-0
13	5-Chloro Thiophene-2-Carboxylic Acid (5-CTC)	-	✓	24065-33-6
Itraconazole Intermediate				
14	2-sec-butyl-4-(4-(4-(4-Hydroxyphenyl) Piperazin-1-yl) Phenyl)2H-1,2,4-triazol-3(4H)-one	-	✓	106461-41-0
15	(4S)-2-((1H-1,2,4,-Triazole-1-yl)Methyl)-2-(2,4-Dichlorophenyl) -1,3-Dioxolan-4-yl)Methyl Methane Sulfonate	-	✓	67914-86-7
Omeprazole Intermediate				
16	Omeprazole Chloro	✓	✓	86604-75-3
17	Omeprazole Sulphide	✓	✓	73590-85-9
18	Omeprazole Benzimidazole	✓	✓	37052-78-1
Pantoprazole Intermediate				
19	Pantoprazole Sulphide	✓	✓	102625-64-9
20	Difluoro Benzimidazole	✓	✓	97963-62-7

SI. No	Product	DMF	Tech Pack	CAS No.
Rabeprazole Intermediate				
21	Rabeprazole Chloro	✓	✓	153259-31-5
22	Rabeprazole Sulphide	✓	✓	117977-21-6
Esomeprazole Intermediate				
23	Di (-) Diethyl Tartarate	✓	✓	13811-71-7
Pregabalin Intermediate				
24	Di acid	✓	✓	75143-89-4
Gancyclovir (Valagan cyclovir Intermediate)				
25	Gancyclovir (Valagan cyclovir Intermediate)	✓	✓	82410-32-0
Pyrimidine Derivative Intermediate				
26	Pyrimidine Derivative	✓	✓	3680-69-1
Sitagliptin intermediate(Pyrazine derivative)				
27	Sitagliptin intermediate(Pyrazine derivative)	✓	✓	767290-92-6
Vonoprazan fumarate Intermediate				
28	5- (2-fluorophenyl) -1- (pyridine-3-sulfonyl) -1-H-pyrrole-3-carbaldehyde	✓	✓	2127152-98-9
Amisulpride Intermediates				
29	1Methyl -4-amino-2-methoxybenzoate			27492-84-8
30	Amino-5-(ethylsulfonyl) -2-methoxybenzoic acid			71675-87-1
Etrasimod intermediates				
31	4-(Chloromethyl)-l-cyclopentyl-2-(trifluoromethyl)benzene2			957208-65-0
32	2-(7-Hydroxy-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)acetate			1206124-13-1
Fezolinetant intermediates				
33	(R)-3-methylpiperzin-2-one			922178-61-8
Mirogabalin Intermediate				
34	2-((1R,5S,6S)-6-cyano-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid			2166206-19-3
Mavacamten intermediates				
35	1-isopropylpyrimidine-2,4,6(1H,3H,5H)-trione			69998-14-78
36	6-chloro-3-isopropylpyrimidine-2,4(1H,3H)-dione			87581-47-7

Oncology Intermediates

Sl. No	Product	DMF	Tech Pack	CAS No.
Pirtobrutinib Intemediate				
1	2-((4-bromophenyl)(methoxy)methylene)malononitrile			1188083-45-5
2	(1S)-2,2,2-trifluoro-1-methylethyl]hydrazine hydrochloride			2764851-03-6
3	5-amino-3-(4-bromophenyl)-1-((S)-1,1,1-trifluoropropan-2-yl)-4,5-dihydro-1H-pyrazole-4-carbonitrile			2101703-39-1
Tucatinib Intermediate				
4	4,4-dimethyl-2-(methylthio)-4,5-dihydrooxazole trifluoromethanesulfonic acid			1384956-50-6
Dabrafenib Intermediate				
5	Methyl 3-((2,6-difluorophenyl)sulfonamido)-2-fluorobenzoate			1195768-19-4
Bortezomib intermediate				
6	(S)-3-Phenyl-2-(pyrazine-2-carboxamido)propanoic acid			114457-94-2
Alectinib Intermediate				
7	Tert-butyl 4-(4-ethyl-3-iodophenyl)-4-methyl-3-oxopentanoate			1256584-74-3
8	Tert-butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate			1256584-75-4
9	4-chloro-3-nitro benzonitrile			939-80-0
Pemetrexed Intermediate				
10	4-[2-(2-Amino-4,7-dihydro-4-Oxo-1H-pymol-[2,3-d]pyrimidin-5-yl)ethyl]benzoic acid			137281-39-1
Aberaterone Base				
11	(3beta)-17-(3-pyridinyl)-androsta-5,16-dien-3-ol			154229-19-3
Ruxolitinib Intermediate				
12	4-chloro-7H-pyrrolo[2,3-d]pyrimidine			3680-69-1
Relugolix Intermediate				
13	4-Nitrophenyl N-methoxy carbomate			68692-38-6
Acalabrutanib intermediate				
14	(4-(phenyl-2-ylcaromoyl)phenyl)boronic acid			850568-25-1

Sl. No Product

- | | | | |
|---|-------------------|---|--------------------------|
| 1 | Ammonium Sulphate | 3 | Di Sodium Orthophosphate |
| 2 | Sodium Nitrite | 4 | Di Ammonium Phosphate |
- ✓ Readily available/ Filed

Note : Above products will not be supplied to countries in which these could be in conflict with existing patents. The final responsibility lies with the buyer

Research & Development (R&D)

Innovating for a Healthier Tomorrow

We believe that the future of healthcare is driven by innovation, cutting-edge research, and a relentless pursuit of excellence. Our Research & Development (R&D) division is at the heart of everything we do, advancing scientific discoveries to bring life-changing medicines and therapies to patients worldwide.

With a dedicated team of scientists, researchers, and clinicians, we are focused on the development of breakthrough treatments across multiple therapeutic areas, including oncology, cardiovascular diseases, neurology, and infectious diseases. Our state-of-the-art facilities, along with strategic collaborations with global institutions, allow us to push the boundaries of modern medicine.

Our R&D Focus:

Innovative Therapies: Creating new molecules and biologics that address unmet medical needs.

Personalized Medicine: Developing treatments tailored to individual patient profiles, ensuring more effective outcomes.

Sustainable Healthcare: Pioneering eco-friendly pharmaceutical production and packaging solutions.

Clinical Excellence: Rigorous clinical trials to ensure safety and efficacy before bringing treatments to market.

we are not just developing medicines; we are creating a healthier, brighter future for patients and their families. Together, we can turn today's challenges into tomorrow's solutions.



CSR Initiative on Water Filtration

As part of its Corporate Social Responsibility (CSR) programme, Everest Organics Limited has installed reverse osmosis (RO) water filtration systems to address the water needs of three local villages. This initiative ensures access to clean and safe drinking water, improving the overall health and quality of life for the residents. Through this project, Everest Organics is contributing to the well-being of the community and promoting sustainable water solutions in rural areas.

Empowering Local Communities through Training and Employment

As part of its ongoing commitment to community development, Everest Organics Limited actively invests in training and skill-building programs for individuals from nearby villages. Locals with relevant academic qualifications are provided with specialized training to enhance their technical and professional skills, ensuring they are well-prepared for the evolving demands of the industry.

These training initiatives focus on upskilling the workforce in areas such as production, quality control, and environmental safety, aligning with Everest Organics' high operational standards. In addition to acquiring valuable skills, participants in the program are given priority when employment opportunities become available within the company. By prioritizing local talent, Everest Organics not only fosters economic growth but also strengthens its bond with the communities it serves.

This initiative reflects Everest Organics Limited's commitment to social responsibility, creating sustainable livelihoods while driving industrial progress and community well-being.



EVEREST


ORGANICS LIMITED



Corporate Office Address:
Everest Organics Limited.
2nd Floor, Dwaraka Heights, Plot No.17,
Jubilee Enclave, Madhapur, Hitech City,
Hyderabad - 500081, Telangana, India.
Tel : 040-48522089.

E-mail: e.api@everestorganicsltd.com

www.everestorganicsltd.com



Scan to visit our site